A randomised Phase I/II trial to evaluate the efficacy and safety of orally administered Oxalobacter formigenes to treat primary hyperoxaluria

被引：0
|
作者：
Bernd Hoppe
Patrick Niaudet
Rémi Salomon
Jérôme Harambat
Sally-Anne Hulton
William Van’t Hoff
Shabbir H. Moochhala
Georges Deschênes
Elisabeth Lindner
Anna Sjögren
Pierre Cochat
机构：
[1] University Hospital Bonn,Department of Pediatrics, Division of Pediatric Nephrology
[2] Université Paris-Descartes,Pediatric Nephrology, Necker Hospital
[3] Centre Hospitalier Universitaire de Bordeaux,Centre de référence Maladies Rénales Rares du Sud
[4] Birmingham Children’s Hospital NHS Foundation Trust,Ouest
[5] Great Ormond Street Hospital,Department of Paediatric Nephrology
[6] Royal Free Campus and Hospital,Renal Unit
[7] Robert Debré Hospital,UCL Centre for Nephrology
[8] OxThera AB,Pediatric Nephrology Department
[9] Hôpital Femme Mère Enfant,Centre de référence des Maladies Rénales Rares
来源：
Pediatric Nephrology | 2017年 / 32卷
关键词：
Primary hyperoxaluria; Oxalate; Kidney; Kidney function;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：781 / 790
页数：9
相关论文
共 50 条
  • [1] A randomised Phase I/II trial to evaluate the efficacy and safety of orally administered Oxalobacter formigenes to treat primary hyperoxaluria
    Hoppe, Bernd
    Niaudet, Patrick
    Salomon, Remi
    Harambat, Jerome
    Hulton, Sally-Anne
    Van't Hoff, William
    Moochhala, Shabbir H.
    Deschenes, Georges
    Lindner, Elisabeth
    Sjogren, Anna
    Cochat, Pierre
    PEDIATRIC NEPHROLOGY, 2017, 32 (05) : 781 - 790
  • [2] A randomised Phase II/III study to evaluate the efficacy and safety of orally administered Oxalobacter formigenes to treat primary hyperoxaluria
    Dawn Milliner
    Bernd Hoppe
    Jaap Groothoff
    Urolithiasis, 2018, 46 : 313 - 323
  • [3] Re: A Randomised Phase I/II Trial to Evaluate the Efficacy and Safety of Orally Administered Oxalobacter formigenes to Treat Primary Hyperoxaluria Editorial Comment
    Assimos, Dean G.
    JOURNAL OF UROLOGY, 2017, 197 (06): : 1463 - 1463
  • [4] A randomised Phase II/III study to evaluate the efficacy and safety of orally administered Oxalobacter formigenes to treat primary hyperoxaluria
    Milliner, Dawn
    Hoppe, Bernd
    Groothoff, Jaap
    UROLITHIASIS, 2018, 46 (04) : 313 - 323
  • [5] Efficacy and safety of Oxalobacter formigenes to reduce urinary oxalate in primary hyperoxaluria
    Hoppe, Bernd
    Groothoff, Jaap W.
    Hulton, Sally-Anne
    Cochat, Pierre
    Niaudet, Patrick
    Kemper, Markus J.
    Deschenes, George
    Unwin, Robert
    Milliner, Dawn
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2011, 26 (11) : 3609 - 3615
  • [6] EPHEX: A PHASE 3 DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMISED STUDY TO EVALUATE LONG-TERM EFFICACY AND SAFETY OF OXALOBACTER FORMIGENES IN PATIENTS WITH PRIMARY HYPEROXALURIA
    Ariceta, Gema
    Schalk, Gesa
    Collard, Laure
    Abroug, Saoussen
    Moochhala, Shabbir
    Gould, Edward
    Boussetta, Abir
    Ben Hmida, Mohamed
    Jarraya, Faical
    Dee, Sudarsana
    Hunley, Tracy E.
    Banos, Ana
    Lindner, Elisabeth
    Dehmel, Bastian
    PEDIATRIC NEPHROLOGY, 2021, 36 (10) : 3304 - 3304
  • [7] Efficacy and safety of Oxalobacter formigenes in patients with primary hyperoxaluria: A systematic review and meta-analysis of randomized controlled trials
    Khan, Ubaid
    Mubariz, Muhammad
    Rezq, Hazem
    Mahmoud, Abdelrahman
    Nasir, Muhammad Moiz
    Ul Ain, Noor
    Bazai, Umar Khan
    Khan, Maleeka Zamurad
    Abuelazm, Mohamed
    INDIAN JOURNAL OF UROLOGY, 2025, 41 (01)
  • [8] ePHex: a phase 3, double-blind, placebo-controlled, randomized study to evaluate long-term efficacy and safety of Oxalobacter formigenes in patients with primary hyperoxaluria
    Ariceta, Gema
    Collard, Laure
    Abroug, Saoussen
    Moochhala, Shabbir H.
    Gould, Edward
    Boussetta, Abir
    Ben Hmida, Mohamed
    De, Sudarsana
    Hunley, Tracy E.
    Jarraya, Faical
    Fraga, Gloria
    Banos, Ana
    Lindner, Elisabeth
    Dehmel, Bastian
    Schalk, Gesa
    PEDIATRIC NEPHROLOGY, 2023, 38 (02) : 403 - 415
  • [9] ePHex: a phase 3, double-blind, placebo-controlled, randomized study to evaluate long-term efficacy and safety of Oxalobacter formigenes in patients with primary hyperoxaluria
    Gema Ariceta
    Laure Collard
    Saoussen Abroug
    Shabbir H. Moochhala
    Edward Gould
    Abir Boussetta
    Mohamed Ben Hmida
    Sudarsana De
    Tracy E. Hunley
    Faical Jarraya
    Gloria Fraga
    Ana Banos
    Elisabeth Lindner
    Bastian Dehmel
    Gesa Schalk
    Pediatric Nephrology, 2023, 38 : 403 - 415
  • [10] Effects of Oxalobacter formigenes in subjects with primary hyperoxaluria Type 1 and end-stage renal disease: a Phase II study
    Hoppe, Bernd
    Pellikka, Patricia A.
    Dehmel, Bastian
    Banos, Ana
    Lindner, Elisabeth
    Herberg, Ulrike
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2021, 36 (08) : 1464 - 1473
12345